Price comparison of tremelimumab and tremelimumab

Tremelimumab and tremelimumab (tremelimumab) are the same drug. Tremelimumab, also called tematumumab, belongs to the monoclonal antibody class of drugs. Its main function is to help the immune system slow or stop the growth of cancer cells. Temtumumab binds to CTLA-4 molecules on T cells, blocking the interaction between CTLA-4 and CD80/CD86, and allowing CD28 molecules on T cells to continue interacting with CD80/CD86 to fully activate T cells, which is required to attack cancer.

In the treatment of hepatocellular carcinoma, it is used in combination with durvalumab (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). In the treatment of non-small cell lung cancer, it is indicated for use in combination with durvalumab (and platinum-containing chemotherapy) for the treatment of adult patients with metastatic non-small cell lung cancer who do not have sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Tremelimumab is only available by prescription, and treatment must be initiated and supervised by a physician experienced in treating cancer.

Tremelimumab/tematumumab is a new type of cancer immunotherapy drug that has not yet been launched in the country, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.